Metastatic hormone-sensitive prostate cancer (mHSPC) is prostate cancer that has spread to distant sites but has not become resistant to androgen deprivation. It is also called metastatic castration-sensitive prostate cancer (mCSPC). The cancer may involve distant lymph nodes, bone or other organs, but it remains responsive to lowering or blocking androgen signaling. This distinction matters because modern first-line treatment usually combines androgen-deprivation therapy (ADT) with an additional effective systemic treatment rather than relying on ADT alone in otherwise suitable patients.
The two parts of the term answer different questions: “metastatic” means M1 disease is present, while “hormone-sensitive” means the cancer has not met criteria for castration-resistant progression while testosterone is suppressed. mHSPC can be newly metastatic at the first diagnosis or can appear years after treatment of earlier localized disease. It can also be low-volume or high-volume, and those distinctions influence whether prostate radiation, an androgen-receptor pathway inhibitor, docetaxel-containing triplet therapy or other treatment strategies are considered.
01What Is Metastatic Hormone-Sensitive Prostate Cancer?
mHSPC combines an anatomical state with a treatment-response state
The abbreviation mHSPC stands for:
- m — metastatic;
- HSPC — hormone-sensitive prostate cancer.
It therefore tells clinicians two different things.
First, distant metastatic disease is present.
Second, the cancer remains in a state where reducing or blocking androgen signaling is clinically effective.
Is mHSPC the same as mCSPC?
In contemporary clinical use, metastatic hormone-sensitive prostate cancer and metastatic castration-sensitive prostate cancer describe the same broad disease state.
The abbreviations are:
- mHSPC;
- mCSPC.
Both distinguish this state from metastatic castration-resistant prostate cancer.
What makes the disease metastatic?
The cancer must have reached a distant site.
Under TNM classification:
- M1a: non-regional lymph-node metastases;
- M1b: bone metastases;
- M1c: another distant metastatic site.
For the full M1 framework, see Metastatic Prostate Cancer.
Are regional pelvic lymph nodes mHSPC?
Not by themselves.
Regional pelvic lymph-node involvement is classified:
N1 M0
if no distant metastasis is present.
That is advanced regional disease, but it is not anatomically M1 metastatic disease.
What does “hormone-sensitive” actually mean?
Most prostate adenocarcinomas depend heavily on androgen-receptor signaling.
Androgens such as testosterone can activate androgen receptors in prostate-cancer cells and support:
- cell survival;
- growth;
- and tumor progression.
mHSPC remains sufficiently dependent on this pathway that suppressing androgen production and/or blocking androgen signaling can produce substantial cancer control.
Does hormone-sensitive mean the cancer is caused by high testosterone?
No.
Hormone-sensitive describes the cancer’s biological dependence on androgen signaling.
It does not mean the patient’s testosterone was abnormally high before diagnosis.
Does testosterone therapy cause mHSPC?
The term mHSPC does not describe how the cancer originally developed.
It describes the current treatment-response state after metastatic disease has been identified.
What is androgen-deprivation therapy?
ADT lowers testicular androgen production or removes that source of androgen production.
It can be achieved with:
- GnRH/LHRH agonists;
- GnRH/LHRH antagonists;
- or bilateral orchiectomy.
Why can an LHRH agonist cause a testosterone flare?
An agonist initially stimulates the pituitary–testicular axis before suppressing it.
This can temporarily raise testosterone before long-term suppression occurs.
In someone with a dangerous metastatic complication—such as impending spinal cord compression or severe urinary obstruction—current European guidance favors approaches that avoid a clinically important flare, such as a GnRH antagonist or orchiectomy.
Hormone-sensitive does not mean “mild.” A patient can have extensive bone or visceral metastases and still have hormone-sensitive disease. The term describes treatment biology, not the amount of cancer.
02What Disease Patterns Matter in mHSPC?
mHSPC can begin as de novo metastatic disease
De novo mHSPC means distant metastases are already present when prostate cancer is first diagnosed.
The primary prostate tumor is still present unless it has been treated separately.
A patient may have:
- bone metastases;
- distant lymph nodes;
- visceral metastases;
- or combinations of these sites.
What is metachronous mHSPC?
Metachronous metastatic disease develops after an earlier nonmetastatic diagnosis.
For example:
localized cancer → prostatectomy → PSA recurrence → later M1 disease.
Or:
localized cancer → radiation → later metastatic recurrence.
This history matters because previous treatment affects the options available now.
What are the common metastatic sites?
The main anatomical categories remain:
- M1a: distant non-regional lymph nodes;
- M1b: bone;
- M1c: other distant sites.
Bone is particularly important in prostate cancer.
For skeletal complications, see Bone Metastases From Prostate Cancer.
What is low-volume metastatic disease?
The term volume comes from clinical-trial classification and is not identical to the TNM M category.
One widely used definition is the CHAARTED system.
What is CHAARTED high-volume disease?
Under CHAARTED criteria, high-volume disease is defined by:
- four or more bone metastases, with at least one outside the vertebral column or pelvis;
- and/or visceral metastasis.
Disease that does not meet the high-volume definition is classified as low volume within this framework.
Do lymph-node metastases alone make disease high volume?
Not under the CHAARTED high-volume definition.
A patient with distant M1a nodal disease but no qualifying visceral or high-volume bone pattern can remain in the low-volume category.
Why does metastatic volume matter?
Volume is clinically relevant because some randomized treatment evidence differs between low- and high-volume populations.
One important example is radiation to the prostate in patients presenting for the first time with M1 disease.
Current European guidance recommends prostate radiotherapy with ADT-based systemic treatment for patients whose first presentation is M1 disease and whose metastatic burden is low by CHAARTED criteria.
Does low-volume metastatic disease mean low-risk cancer?
No.
Low volume describes the distribution of metastases under a trial definition.
It does not mean:
- low Grade Group;
- low PSA;
- slow cancer;
- or a guarantee of favorable prognosis.
What is high-risk metastatic disease?
Some trials use risk definitions rather than volume definitions.
The LATITUDE high-risk definition, for example, is based on a combination of:
- high pathological grade;
- multiple bone metastases;
- and visceral disease.
Risk and volume overlap, but they are not identical classification systems.
Why is conventional imaging important when reading these definitions?
The major randomized trials that established low- versus high-volume treatment effects generally used conventional staging such as:
- CT;
- MRI;
- and bone scintigraphy.
Modern PSMA PET/CT can reveal small metastatic deposits that older imaging would miss.
This can move a patient from apparently nonmetastatic disease into an M1 category without necessarily making that patient biologically equivalent to the high-volume populations studied in older trials.
Do not translate PSMA-PET lesion counts mechanically into old trial categories without clinical context. The treatment evidence defining CHAARTED volume and the benefit of prostate radiotherapy was generated largely with conventional CT/MRI and bone-scan staging.
03How Is Metastatic Hormone-Sensitive Prostate Cancer Treated?
ADT remains the foundation—but usually not the entire treatment
For decades, ADT alone was the standard initial treatment for metastatic hormone-sensitive disease.
Randomized trials later showed that outcomes improve when suitable patients receive more complete initial treatment.
Current European guidance therefore advises against routine ADT monotherapy for patients presenting with M1 disease who:
- have no contraindication to combination therapy;
- have sufficient life expectancy to benefit;
- and accept the increased treatment burden and potential side effects.
What treatments are commonly added to ADT?
Guideline-supported androgen-receptor pathway treatment can include, depending on approval and patient factors:
- abiraterone acetate with corticosteroid support;
- apalutamide;
- enzalutamide;
- darolutamide;
- or other approved regional options.
These treatments either:
- further suppress androgen production;
- or block androgen-receptor signaling inside the cancer cell.
Why isn’t an older antiandrogen by itself enough?
Androgen-receptor antagonist monotherapy does not suppress the androgen pathway as effectively as modern ADT-based combinations and is not recommended as sole therapy for M1 disease.
What is doublet therapy?
In modern mHSPC, a common doublet is:
ADT + an androgen-receptor pathway inhibitor.
This strategy can be appropriate across a broad range of metastatic volumes, including many patients with:
- bone metastases;
- nodal disease;
- de novo metastases;
- or metastases recurring after earlier local treatment.
What is triplet therapy?
Triplet therapy adds chemotherapy to deeper androgen-pathway blockade:
ADT + docetaxel + an additional androgen-receptor pathway treatment.
Large randomized trials such as PEACE-1 and ARASENS established the value of evidence-based triplet regimens in appropriately selected metastatic patients.
Who is more likely to be considered for triplet therapy?
The decision is individualized, but the discussion becomes particularly relevant in fit patients with:
- de novo metastatic disease;
- high-volume disease;
- high-risk metastatic characteristics;
- rapidly progressive disease;
- and sufficient physiological reserve for chemotherapy.
Is docetaxel plus ADT alone still the preferred chemotherapy strategy?
Current EAU guidance has moved toward using docetaxel as part of a triplet regimen when an appropriate androgen-receptor pathway inhibitor is available and the patient is fit for chemotherapy.
ADT plus docetaxel alone may still arise in settings where:
- modern androgen-receptor pathway treatment is unavailable;
- contraindicated;
- or limited by other patient-specific considerations.
Does every mHSPC patient need chemotherapy?
No.
Many patients can receive highly effective:
ADT + androgen-receptor pathway inhibitor
without docetaxel.
Chemotherapy fitness depends on:
- performance status;
- age in biological rather than chronological terms;
- bone marrow reserve;
- neuropathy;
- comorbidities;
- infection risk;
- and patient preferences.
Can the prostate itself be treated when distant metastases already exist?
Yes, in a defined clinical setting.
For patients whose first presentation is M1 disease and who have low-volume metastases by CHAARTED criteria, current EAU guidance recommends adding radiotherapy to the prostate to ADT-based systemic therapy.
Why can prostate radiation help if cancer has already spread?
Randomized evidence shows that treating the primary prostate can improve outcomes in selected low-burden metastatic populations.
It may also reduce important local complications such as:
- urinary obstruction;
- bleeding;
- and the need for local urinary procedures.
Does prostate radiation replace systemic treatment?
No.
Once M1 disease exists, metastatic cancer cells are outside the prostate.
Radiation to the prostate therefore complements rather than replaces systemic treatment.
Should the prostate be surgically removed in mHSPC?
Radical prostatectomy is not established as routine treatment for M1 disease.
Current EAU guidance recommends against combining ADT with prostate surgery for M1 patients outside clinical trials.
What about treating individual metastases with SBRT?
Metastasis-directed therapy can control selected lesions and has shown promising progression-related outcomes in oligometastatic research.
However, current EAU guidance still places metastasis-directed therapy for M1 disease within:
- clinical trials;
- or well-designed prospective cohort settings.
It should not be presented as a proven substitute for systemic mHSPC treatment.
Does genetic testing matter this early?
Yes.
Metastatic prostate cancer increasingly warrants early consideration of:
- germline genetic testing;
- and tumor or circulating-DNA genomic testing.
Relevant alterations can include genes involved in homologous-recombination repair, such as:
- BRCA2;
- BRCA1;
- ATM;
- and related repair genes.
These results can affect current or future targeted-treatment options and may also carry implications for relatives when a germline pathogenic variant is found.
For inherited-risk context, see BRCA1, BRCA2 and Prostate Cancer.
Why does supportive care begin at the same time?
ADT and metastatic disease both affect health beyond the tumor itself.
Long-term care may include:
- bone-density assessment;
- fracture-risk evaluation;
- exercise and resistance training when safe;
- weight and metabolic monitoring;
- blood-pressure management;
- diabetes and cardiovascular-risk assessment;
- sexual-health support;
- fatigue management;
- and psychological support.
What are common ADT side effects?
Potential effects include:
- hot flashes;
- loss of libido;
- erectile dysfunction;
- loss of muscle mass;
- increased body fat;
- bone-density loss;
- fatigue;
- insulin resistance;
- changes in blood lipids;
- and mood or cognitive effects in some patients.
The treatment question is no longer simply “ADT or chemotherapy?” Modern mHSPC care compares effective combinations: ADT plus an androgen-receptor pathway inhibitor for many patients, triplet therapy for selected chemotherapy-fit patients, and prostate radiation for appropriate newly diagnosed low-volume disease.
Symptomatic metastatic complications may require treatment before the full long-term plan is finalized. New neurological deficits from suspected spinal cord compression, pathological fracture, severe urinary obstruction or uncontrolled metastatic pain require prompt clinical management.
04How Is mHSPC Monitored, and When Does It Become Castration-Resistant?
Response is monitored with more than PSA
PSA is extremely useful during mHSPC treatment, but it should not be the only measure of disease control.
Monitoring can include:
- PSA;
- serum testosterone;
- symptoms;
- physical function;
- blood counts;
- kidney and liver function;
- alkaline phosphatase in relevant bone-metastatic disease;
- and repeat imaging when clinically indicated.
Why measure testosterone?
If prostate cancer appears to be progressing during ADT, clinicians need to know whether testosterone has actually been adequately suppressed.
A patient whose testosterone has escaped suppression has a different problem from a patient whose tumor is progressing despite a castrate testosterone level.
Does a major PSA fall mean treatment is working?
A substantial PSA decline is generally encouraging and can provide useful prognostic information.
However, PSA response does not guarantee that:
- every metastasis is shrinking;
- the cancer will remain hormone-sensitive indefinitely;
- or radiographic progression cannot occur.
Can metastatic prostate cancer progress without PSA rising much?
Yes.
Radiographic progression can occur without a parallel PSA increase.
This is one reason clinical symptoms and imaging remain important during long-term metastatic care.
What is castration-resistant prostate cancer?
Castration-resistant prostate cancer develops when cancer progresses despite adequately suppressed testosterone.
Current EAU criteria use:
serum testosterone below 50 ng/dL (1.7 nmol/L)
together with evidence of:
- biochemical progression;
- radiographic progression;
- or unequivocal clinical progression.
Does castration-resistant mean testosterone is high again?
No.
It means the opposite:
the cancer is progressing even though testosterone remains suppressed.
Does the cancer stop using androgen receptors when it becomes resistant?
Not necessarily.
Castration-resistant tumors can remain highly dependent on androgen-receptor biology through mechanisms such as:
- increased androgen-receptor expression;
- receptor changes;
- intratumoral androgen production;
- alternative receptor signaling;
- and selection of treatment-resistant cancer-cell populations.
That is why androgen suppression is generally continued even after the disease becomes castration-resistant.
Does every patient with mHSPC become mCRPC?
Progression risk is substantial, but timing varies widely.
Some patients remain controlled for prolonged periods, while others develop resistance relatively quickly.
Important influences include:
- metastatic volume;
- visceral disease;
- Grade Group;
- timing of metastasis;
- genomic biology;
- depth of PSA response;
- and treatment response.
What happens when mCRPC develops?
The disease remains metastatic, but the treatment framework changes.
Clinicians then consider:
- what therapies were already used during mHSPC;
- how long each treatment controlled the cancer;
- where progression is occurring;
- whether symptoms are present;
- genomic findings;
- PSMA expression;
- chemotherapy fitness;
- and blood-count and organ-function reserve.
The next dedicated guide addresses this castration-resistant metastatic state.
Why is imaging still needed when PSA looks good?
Some patients can develop radiographic progression without a proportionate PSA increase.
Imaging decisions are individualized according to:
- symptoms;
- initial metastatic burden;
- treatment response;
- PSA behavior;
- and whether the result would change treatment.
What else should be monitored during long-term treatment?
Because mHSPC treatment may continue for years, surveillance also includes treatment toxicity.
Depending on the regimen, clinicians may monitor:
- blood pressure;
- blood glucose;
- lipids;
- weight and waist circumference;
- liver tests;
- potassium;
- blood counts;
- bone density;
- fracture risk;
- muscle function;
- cardiovascular health;
- fatigue;
- sexual health;
- and quality of life.
mHSPC and mCRPC are sequential treatment states, not different places in the body. Both can be anatomically M1. The transition occurs when cancer begins progressing despite adequate androgen suppression, which changes the systemic-treatment strategy.
→mHSPC Classification and Treatment Context at a Glance
| Clinical feature | Meaning | Why it matters |
|---|---|---|
| mHSPC / mCSPC | M1 prostate cancer that remains sensitive to androgen suppression. | ADT-based combination therapy is the first-line systemic framework. |
| De novo metastatic | M1 disease is present at initial prostate-cancer diagnosis. | Primary-prostate treatment and triplet therapy discussions may differ from later metastatic recurrence. |
| Metachronous metastatic | M1 disease develops after previous nonmetastatic diagnosis or local treatment. | Previous surgery, radiation and systemic therapy influence current treatment. |
| M1a | Non-regional lymph-node metastasis. | Metastatic disease even without bone or visceral involvement. |
| M1b | Bone metastasis. | Requires attention to skeletal pain, fracture risk and spinal complications in addition to systemic therapy. |
| M1c | Other distant metastatic site. | Visceral involvement can indicate more aggressive disease biology and affects treatment context. |
| CHAARTED low volume | Does not meet the trial definition of high-volume metastatic disease. | Relevant to evidence supporting prostate radiation in newly diagnosed M1 disease. |
| CHAARTED high volume | Visceral metastasis and/or ≥4 bone metastases with ≥1 outside vertebral column or pelvis. | Higher disease burden; often strengthens the discussion around systemic intensification. |
| ADT + ARPI | Deeper androgen-pathway suppression. | Modern first-line standard for many suitable mHSPC patients. |
| Triplet therapy | ADT + ARPI + docetaxel. | Considered particularly in selected fit patients with de novo and/or high-volume/high-risk disease. |
| mCRPC transition | Progression despite castrate testosterone. | Changes the systemic-treatment state and subsequent sequencing strategy. |
?Common Questions About mHSPC
| Question | Practical answer |
|---|---|
| What does mHSPC stand for? | Metastatic hormone-sensitive prostate cancer. |
| What does mCSPC stand for? | Metastatic castration-sensitive prostate cancer. |
| Are mHSPC and mCSPC the same? | They are commonly used for the same broad metastatic treatment-response state. |
| What does metastatic mean? | Prostate cancer has reached a distant site and is classified M1. |
| What does hormone-sensitive mean? | The cancer still responds clinically to suppression or blockade of androgen signaling. |
| Does hormone-sensitive mean the cancer is early? | No. mHSPC can include extensive bone or visceral metastases. |
| Does hormone-sensitive mean testosterone was too high? | No. It describes tumor biology rather than the cause of the cancer. |
| Where can mHSPC spread? | Distant lymph nodes, bone and other distant organs. |
| What is M1b? | Bone-metastatic prostate cancer. |
| Are pelvic lymph nodes mHSPC? | Regional pelvic nodes alone are N1 M0 rather than M1. |
| What is de novo mHSPC? | Metastatic hormone-sensitive disease present when prostate cancer is first diagnosed. |
| What is metachronous mHSPC? | Metastases developing after an earlier localized or nonmetastatic prostate-cancer diagnosis. |
| What is low-volume metastatic disease? | Disease that does not meet the CHAARTED high-volume definition. |
| What is CHAARTED high-volume disease? | Visceral metastasis and/or at least four bone metastases with at least one beyond the vertebral column or pelvis. |
| Does low volume mean low risk? | No. Metastatic volume and biological risk are different concepts. |
| How is mHSPC treated? | ADT is the foundation, usually combined with an additional androgen-receptor pathway treatment in suitable patients. |
| Is ADT alone enough? | For most suitable patients presenting with M1 disease, current guidelines favor combination treatment rather than routine ADT monotherapy. |
| What drugs can be added to ADT? | Depending on approval and patient factors, options include abiraterone, apalutamide, enzalutamide, darolutamide and other guideline-supported regional treatments. |
| What is an ARPI? | An androgen-receptor pathway inhibitor—treatment that suppresses androgen production or blocks androgen-receptor signaling more completely. |
| What is triplet therapy? | ADT plus docetaxel plus an additional androgen-receptor pathway treatment. |
| Does everyone with mHSPC need docetaxel? | No. Chemotherapy is selected according to disease pattern, fitness, expected benefit and patient preferences. |
| Can the prostate still be irradiated after metastases are found? | Yes. Prostate radiation is recommended for selected patients presenting with low-volume M1 disease by CHAARTED criteria. |
| Does prostate radiation replace systemic treatment? | No. M1 disease still requires a systemic-treatment strategy. |
| Is prostatectomy routine for mHSPC? | No. Current EAU guidance does not recommend prostate surgery for M1 disease outside clinical trials. |
| Can individual metastases be treated with SBRT? | It may be studied or used in carefully selected prospective settings, but it should not replace evidence-based systemic treatment. |
| Why test BRCA genes in metastatic disease? | Inherited or tumor DNA-repair abnormalities can affect targeted-treatment options and sometimes have implications for relatives. |
| How do doctors know ADT is working? | They assess PSA, testosterone, symptoms, laboratory tests and imaging when appropriate. |
| Can the cancer progress even if PSA is not rising much? | Yes. Radiographic progression can sometimes occur without a parallel PSA rise. |
| What does castrate testosterone mean? | EAU criteria for CRPC use a testosterone level below 50 ng/dL, or 1.7 nmol/L. |
| When does mHSPC become mCRPC? | When metastatic cancer demonstrates biochemical, radiographic or unequivocal clinical progression despite castrate testosterone. |
| Does mCRPC mean testosterone has recovered? | No. It means progression is occurring while testosterone remains suppressed. |
| Does ADT stop when castration resistance develops? | Usually no. Androgen suppression is generally maintained while the next systemic treatment is selected. |
| Can mHSPC be controlled for years? | Yes. Duration of control varies considerably according to disease burden, biology and treatment response. |
| What determines prognosis? | Important factors include metastatic sites and volume, Grade Group, timing of metastasis, PSA response, genomic biology, symptoms, overall health and response to treatment. |
ΣKey Clinical Takeaways
- mHSPC means metastatic hormone-sensitive prostate cancer.
- mCSPC is another commonly used term for the same broad disease state.
- The disease is metastatic, meaning M1 cancer is present.
- Hormone-sensitive means the cancer remains responsive to suppression of androgen signaling.
- Hormone sensitivity describes tumor biology rather than metastatic burden.
- A patient can have extensive metastases and still have hormone-sensitive disease.
- M1a means non-regional lymph-node metastasis.
- M1b means bone metastasis.
- M1c means another distant metastatic site.
- Regional pelvic lymph nodes alone are N1 rather than M1.
- mHSPC can be de novo at the first prostate-cancer diagnosis.
- It can also develop metachronously after previous treatment for nonmetastatic disease.
- The distinction between de novo and metachronous disease can influence treatment planning.
- Metastatic volume is separate from TNM stage.
- CHAARTED high-volume disease includes visceral metastasis and/or at least four bone metastases with at least one outside the vertebral column or pelvis.
- Disease not meeting that definition is low volume within the CHAARTED framework.
- Low-volume metastatic disease is not the same as low-risk prostate cancer.
- Original volume definitions were developed mainly with conventional imaging.
- PSMA PET can reveal small lesions that were invisible on older staging tests.
- ADT is the treatment foundation for mHSPC.
- Modern care generally intensifies ADT with another effective treatment in suitable patients.
- Abiraterone, apalutamide, enzalutamide and darolutamide are among androgen-pathway treatments used in mHSPC, subject to patient factors and regulatory availability.
- ADT plus an androgen-receptor pathway inhibitor is an established modern doublet approach.
- Triplet therapy adds docetaxel to ADT plus an androgen-pathway treatment.
- Triplet therapy is not required for every patient.
- Chemotherapy fitness, metastatic burden, timing, symptoms and patient preference matter.
- Current EAU guidance favors docetaxel as part of an appropriate triplet rather than routine ADT-docetaxel doublet treatment when effective ARPI therapy can be used.
- Prostate radiotherapy has a treatment role in selected patients presenting with low-volume M1 disease.
- Radiation to the primary prostate does not replace systemic therapy.
- Routine prostatectomy for M1 disease is not established outside clinical trials.
- Metastasis-directed therapy remains more investigational than standard systemic treatment for established M1 disease.
- Metastatic patients increasingly benefit from early germline and somatic genomic assessment.
- BRCA and other homologous-recombination repair alterations can influence later targeted-treatment options.
- PSA is important for monitoring but is not sufficient by itself.
- Radiographic progression can occur without a major PSA rise.
- Serum testosterone should be checked when treatment resistance is suspected.
- Castration-resistant disease is progression despite adequately suppressed testosterone.
- EAU CRPC criteria use testosterone below 50 ng/dL or 1.7 nmol/L together with evidence of progression.
- Castration resistance does not mean testosterone has returned to normal.
- ADT is generally continued after the cancer becomes castration-resistant.
- Long-term mHSPC management must also address bone density, metabolic health, cardiovascular risk, physical function, sexual health and quality of life.
- mHSPC can remain controlled for prolonged periods, but duration varies substantially among patients.
- The next treatment decision should be based on disease state, metastatic pattern, previous treatment, biomarkers and patient health rather than the abbreviation mHSPC alone.
Clinical bottom line: metastatic hormone-sensitive prostate cancer is M1 prostate cancer that remains responsive to androgen suppression. Modern treatment uses ADT as the foundation but usually intensifies the androgen pathway with an additional therapy rather than relying on ADT alone in otherwise suitable patients. The most useful treatment description then adds the metastatic pattern—bone, distant nodes or visceral disease—the timing of metastasis, low- versus high-volume burden, chemotherapy fitness and genomic information. Selected fit patients may receive triplet treatment, while prostate radiotherapy has a specific role in newly diagnosed low-volume M1 disease. Over time, monitoring must include testosterone, PSA, symptoms and imaging because the defining next transition is progression despite castrate testosterone: castration-resistant prostate cancer.
Medical disclaimer: This article provides general medical education about metastatic hormone-sensitive prostate cancer. Treatment depends on metastatic burden and location, symptoms, previous prostate-cancer therapy, age and physiological fitness, cardiovascular and metabolic health, bone health, kidney and liver function, genomic findings, local drug approvals and individual treatment priorities. Systemic treatment should be selected with specialist urology and oncology input.
For the anatomical definition and M1a/M1b/M1c categories, review Metastatic Prostate Cancer. For the skeletal disease most commonly associated with M1b progression, see Bone Metastases From Prostate Cancer. For the broader distinction between localized, locally advanced, recurrent and metastatic disease, review Prostate Cancer Stages and Advanced Prostate Cancer. For pathology grade, see What Is the Gleason Score? and Gleason Score vs Grade Group. For inherited DNA-repair risk relevant to selected metastatic treatment decisions, review BRCA1, BRCA2 and Prostate Cancer. For PSA behavior during progression, see PSA Testing and PSA Doubling Time. For the complete prostate-cancer framework, return to the Prostate Cancer hub. The next guide explains metastatic castration-resistant prostate cancer—how resistance is defined, why ADT continues and how treatment changes after progression despite castrate testosterone.
Evidence Sources
- European Association of Urology — Prostate Cancer Treatment: current first-line recommendations for metastatic hormone-sensitive disease, ADT intensification, androgen-receptor pathway inhibitors, triplet treatment, low-volume prostate radiotherapy, molecular testing and supportive care.
- European Association of Urology — Classification and Staging Systems: TNM metastatic categories and the distinction between anatomical stage and pathological grade.
- European Association of Urology — Diagnostic Evaluation: metastatic imaging, conventional staging and PSMA PET/CT.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: androgen deprivation, metastatic castration-sensitive disease, androgen-receptor pathway treatment and treatment side effects.
- National Cancer Institute — Prostate Cancer Treatment, Health Professional Version: randomized evidence for ADT combinations, chemotherapy and treatment of metastatic prostate cancer.
- National Cancer Institute — Prostate Cancer Treatment PDQ for Patients: hormone therapy and systemic treatment of advanced and metastatic prostate cancer.
- National Cancer Institute — Advances in Prostate Cancer Research: androgen-receptor pathway treatment, metastatic disease and development of castration resistance.
